- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01938495
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) (DPS in ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
The study is being conducted to determine if DPS treatment for people with ALS and hypoventilation is associated with improved survival or diaphragm function.
The primary objective of the study is to conduct a multi-center, randomized controlled clinical trial comparing standard of care (control) to diaphragm stimulator treatment with the NeuRx® Diaphragm Pacing System™ (DPS) with respect to survival.
The secondary objective of the study is to conduct a multi-center, randomized controlled clinical trial to compare standard of care treatment (control) to DPS in ALS subjects with hypoventilation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized controlled study to compare standard of care (control) to DPS (diaphragm stimulator named The NeuRx® Diaphragm Pacing System™). Although it remains uncertain if DPS is efficacious for the ALS subject, given the preliminary studies performed by the device manufacturer, it has received FDA humanitarian device exemption (HDE) approval as a humanitarian use device (HUD). This study will utilize a 2:1 randomization schedule such that eligible ALS subjects will have a 2/3 chance of receiving DPS and 1/3 chance of standard of care (control) treatment.
The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States
- Barrow Neurological Institute
-
-
California
-
Los Angeles, California, United States
- Cedars-Sinai Medical Center
-
San Diego, California, United States
- California Pacific Medical Center
-
Stanford, California, United States
- Stanford University
-
-
Connecticut
-
New Britain, Connecticut, United States
- Hospital for Special Care
-
-
Florida
-
Jacksonville, Florida, United States
- Mayo Clinic Florida
-
Jacksonville, Florida, United States
- University of Florida, Jacksonville
-
-
Iowa
-
Iowa City, Iowa, United States
- University of Iowa
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States
- Henry Ford Health Systems
-
-
Missouri
-
Saint Louis, Missouri, United States
- St Louis University
-
-
Nebraska
-
Lincoln, Nebraska, United States
- Neurology Associates P.C.
-
-
New York
-
New York, New York, United States
- Hospital for Special Surgery
-
Syracuse, New York, United States
- SUNY Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, United States
- Carolinas Health Care
-
Winston-Salem, North Carolina, United States
- Wake Forest University
-
-
Ohio
-
Cleveland, Ohio, United States
- Cleveland Clinic
-
Columbus, Ohio, United States
- Ohio State University
-
-
Oregon
-
Portland, Oregon, United States
- Providence ALS Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Drexel University
-
Pittsburgh, Pennsylvania, United States
- University of Pittsburgh
-
-
Texas
-
Dallas, Texas, United States
- University of Texas Southwestern
-
San Antonio, Texas, United States
- University of Texas
-
-
Vermont
-
Burlington, Vermont, United States
- University of Vermont
-
-
Washington
-
Seattle, Washington, United States
- Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 21 years or older.
- Sporadic or familial ALS diagnosed as definite, probable or possible ALS as defined by revised El Escorial criteria.
Evidence of hypoventilation at Screening with at least one of the following:
- Maximal static inspiratory pressure (MIP) <60 cm H20.
- Upright or supine forced vital capacity (FVC) <50% predicted for gender, age, and height.
- A phrenic nerve potential should be recordable bilaterally.
- Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to randomization (riluzole-naïve subjects are permitted in the study).
- Capable of providing informed consent and following trial procedures.
- Geographically accessible to the site.
- Negative urine pregnancy test at Screening in women of child bearing potential (WOCBP). (Women who are post-menopausal or who have had a hysterectomy are deemed not of child bearing potential).
- Women of child bearing potential must use an adequate form of contraception: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.
Exclusion Criteria:
- Upright forced vital capacity (FVC) ≤ 45% of predicted for gender, age, and height.
- Any prior use of non-invasive ventilation (NIV) outside of sleep (nighttime or naps).
- Any pulmonary or cardiac disorder or other medical disorder that would be a contraindication for general anesthesia or DPS hardware implantation in the chest.
- Implanted electrical device such as a pacemaker or cardiac defibrillator.
- Known diaphragm abnormality such as hiatal hernia or para-esophageal hernia of abdominal contents into the thoracic cavity.
- Participation in another treatment research study for people with ALS.
- Exposure to any other agent currently under investigation for the treatment of people with ALS (off-label use or investigational) within 30 days of the Screening Visit.
- Clinically significant history of unstable or severe cardiac, oncologic, hepatic, psychiatric, renal disease, or other medically significant illness.
- Pregnant women or women currently breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NeuRx® Diaphragm Pacing System™ (DPS)
Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device.
Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
|
The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system.
Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc.
Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm.
The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
|
No Intervention: Standard of Care
patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survival
Time Frame: Subjects will be assessed on a monthly basis for an 18 month period.
|
Subjects will be assessed on a monthly basis for an 18 month period.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
quality of life
Time Frame: Subjects will be assessed on a monthly basis for an 18 month period.
|
Subjects will be assessed on a monthly basis for an 18 month period.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeremy Shefner, MD, PhD, Barrow Neurological Institute
- Principal Investigator: Jonathan Katz, MD, California Pacific Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013P001504
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis (ALS)
-
Dallas VA Medical CenterRecruitingAmyotrophic Lateral Sclerosis (ALS)United States
-
St. Joseph's Hospital and Medical Center, PhoenixEmory University; Mitsubishi Tanabe Pharma America Inc.Active, not recruitingALS (Amyotrophic Lateral Sclerosis)United States
-
Taipei Veterans General Hospital, TaiwanUnknownDevelopment and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.ALS (Amyotrophic Lateral Sclerosis)Taiwan
-
Brainstorm-Cell TherapeuticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Phoenix Neurological Associates, LTDInstitute for EthnomedicineUnknown
-
Skulpt, Inc.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Northwestern UniversityCompletedAmyotrophic Lateral Sclerosis (ALS) | Lou Gehrig's Disease | Primary Lateral Sclerosis (PLS) | Familial Amyotrophic Lateral Sclerosis | ALS With Frontotemporal Dementia (ALS/FTD) | Motor Neuron Disease (MND) | Sporadic ALS (SALS)United States
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
Clinical Trials on NeuRx® Diaphragm Pacing System™ (DPS)
-
Synapse BiomedicalWithdrawnTracheostomy | Ventilator-Induced Lung Injury | Diaphragm IssuesTurkey
-
Synapse BiomedicalWithdrawnAmyotrophic Lateral Sclerosis
-
Synapse BiomedicalCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Synapse BiomedicalCompletedChronic Obstructive Airway DiseaseBelgium
-
Institut GuttmannCompletedAmyotrophic Lateral Sclerosis | Spinal Cord Injuries | Respiratory Paralysis
-
Lungpacer Medical Inc.TerminatedVentilator Induced Diaphragm DysfunctionUnited States, France, Germany
-
AO Innovation Translation CenterNot yet recruitingFracture | Clavicle | Acromioclavicular JointGermany, United Kingdom
-
Lungpacer Medical Inc.SyntactxCompletedVentilator Induced Diaphragm DysfunctionUnited States
-
Boston Scientific CorporationCompletedVasovagal Syncope | Arhythmia | Atrioventricular Heart-block | Chronic Bundle Branch or Branch Block | Carotid Sinus Hypersensitivity Reaction SyndromeChina
-
Cardica, IncCompletedHeart DiseaseUnited States